Latest News
  • eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
  • Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics
  • Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing
  • eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
cancer treatment images
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Belgium-based eTheRNA immunotherapies has established a collaboration and licence agreement with Ghent University for mRNA delivery with enhanced thermostability, biodegradability and safety. eTheRNA will receive worldwide commercialisation rights for the new generation of lipid nanoparticle (LNP) formulations co-developed with the university’s research group […]

CMO Image Blog Article

What’s New in the Biologics CMO Space in APAC?

by

Excerpt: As more biologics products enter and exit clinical development and into the market in the APAC region, the opportunities for CMOs to fulfil production requirements are burgeoning. There is an increase in demand for innovative process technologies to meet the demand. Biopharmaceutical companies in APAC are moving away from in-house manufacturing and recruiting CMOs […]

cell therapy blog image

Notable Players in the APAC Cell Therapy Manufacturing Space

by

Excerpt Key drivers such as fund and regulatory support from the government, improved market access and healthcare infrastructure and more are currently fueling growth in APAC’s cell therapy market. The enactment of the Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine in August 2020, the increased market access can be […]

Southeast Asia map

Addressing The Rapidly Growing Southeast Asia Bioprocessing Market

by

Excerpt Singapore has been receiving notable investments in facility set-up and expansion. Thailand is seeing increase in the demand for viral vector manufacturing and the production of plasmid DNA and fusion proteins. While the biotech industry is still in its infancy in countries like Indonesia and Vietnam, there has been emphasis on development of biotech […]

bioprocessing facilities article

APAC Bioprocessing Facilities Market Trends This 2021

by

Excerpt 36% of all bioprocessing facilities in the Asia Pacific are engaged in the manufacturing of novel monoclonal antibodies. More than 40% of the manufacturing facilities in APAC have progressed from establishment to operations within the past 2 years. Biopharmaceutical companies in APAC are inclined towards adopting more process innovation technologies while expanding their facilities. […]

Cytovia-Therapeutics-Logo

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

by

Excerpt $45 million in financing has been secured by Cytovia and its China-focused joint venture CytoLynx, to advance their Natural Killer (NK) cell therapy for global commercialisation. TF Capital, together with Cytovia, have formed CytoLynx, and the venture is further supported by YF Capital, BioTrack Capital, Ruihua Capital and YG Sino-Dragon Fund. This will accelerate […]

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

by

Excerpt Positive interim analysis of safety and efficacy from the first 30% of enrolled patients evaluated 12 months post-treatment in a Phase 3 clinical trial (SALAMANDER) of REX-001 has resulted in the independent Data Monitoring Committee (DMC) recommending the unchanged continuation of the trial. REX-001, an autologous multi-cell therapy (MCT), is being developed for the […]

Tree Frog Therapeutics Blog

TreeFrog Therapeutics secures $75m in Series B financing to advance a pipeline of Stem Cell-Derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan

by

Excerpt Pursuant to securing $75 million in Series B funding, TreeFrog Therapeutics names Frederic Desdouits, PhD, as CEO and announces that co-founder Kevin Alessandri, PhD, is to relocate to Boston to drive TreeFrog’s expansion in the U.S. The funding was led by Bpifrance Large Venture, together with Leonard Green & Partners L.P., Bristol Myers Squibb […]

Biosimilar producer looking to get first to market advantage in China and Europe

Biosimilar producer looking to get first to market advantage in China and Europe

by

Excerpt Bio-Thera Solutions, a biopharmaceutical company based in Guangzhou, China, has initiated the first Phase 3 study of a golimumab biosimilar in China and Eastern Europe, which is expected to enrol 598 subjects and achieve completion by October 2023. As the first golimumab biosimilar to gain approval in multiple countries, BAT2506 gives Bio-Thera Solutions early […]

Updated Biothera Blog

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)

Excerpt Bio-Thera Solutions and Sandoz have entered a commercialisation and license agreement for BAT1706, a monoclonal antibody that is a proposed biosimilar referencing AVASTIN® (bevacizumab). Under the terms of the agreement, Bio-Thera will develop, manufacture and supply BAT1706 and Sandoz will market the bevacizumab biosimilar in markets covered by the agreement.  Article Bio-Thera Solutions has […]

Adaptimmune Enters into a Strategic Collaboration with Genentech

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Excerpt An agreement between Adaptimmune and Genentech is set to drive “off-the-shelf” cancer-targeted cell therapy advancements and commercialization with an initial payment of $150 million to Adaptimmune. The partnership also aims to develop a first-of-its-kind personalized cell therapy platform to enable patients to receive curated T-cell products for their individual cancer treatment needs. Adaptimmune may […]

AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

Excerpt AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach […]

Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability

Excerpt I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company […]

Explore IMAPAC

    padlock

    By clicking the "Submit" button, you are agreeing to IMAPAC's Privacy Policy.

    Events

    Thought leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

    Intelligence

    In-depth biopharmaceutical industry intelligence brought to you by our team of analysts.

    LeadGen 360

    Expand your influence, be it through branding & display ads, content creation or thought leadership.

    Community

    Linking professionals and fostering conversations among the biopharmaceutical industry professionals.
    bag